St John of God Hospital in Dublin has said it is the first hospital in Ireland to introduce a special treatment for patients ...

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) revealed the topline data from the Phase 2b study of SPN-820 in adults with ...

The company announced on 18 February that the trial did not meet its primary endpoint measured by a depression rating scale, ...

A new non-invasive treatment for depression, which has been shown to deliver remission for one third of its patients, is to ...

Ketamine, a non-competitive N-methyl-D-aspartate receptor antagonist, has emerged as an effective therapeutic agent for the management of treatment-resistant depression. Repeated treatments with ...

Faster-acting drugs have long been sought to protect people with severe depression who may be at risk of self-harm or suicide ...

Some of our patients often tell us they need to experience some undesirable truth first-hand to believe it. Implied is the ...

Major depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing to treatment-resistant depression (TRD).

IntroductionMajor depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing ...

Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS ...

Ketamine, a dissociative anesthetic, has carved itself a spot in the world of mental health care over the past two decades.

Bright Minds Biosciences has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at ...